These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 16279641)

  • 1. [Perspective for the new calcitonin preparation].
    Yamauchi H
    Nihon Rinsho; 2005 Oct; 63 Suppl 10():246-9. PubMed ID: 16279641
    [No Abstract]   [Full Text] [Related]  

  • 2. [Intranasal absorption of various calcitonin spray preparations].
    Pisati P; Feletti F; De Bernardi M; Tripodi AS; Contos S; Germogli R; Molteni R; Covini D
    Boll Chim Farm; 1992 Mar; 131(3):120-7. PubMed ID: 1418891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic effects of carbocalcitonin and salmon calcitonin, after endonasal administration in man.
    Cecchettin M; Segre G
    Biomed Pharmacother; 1995; 49(4):215-8. PubMed ID: 7669941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intranasal calcitonin].
    Gava R; Luisetto G; Beltrami GC; Grezzana L
    G Clin Med; 1989 Apr; 70(4):285-91. PubMed ID: 2767367
    [No Abstract]   [Full Text] [Related]  

  • 5. [Transmucosal delivery system of calcitonin].
    Takama S; Hibi T; Konishi R
    Nihon Rinsho; 1989 Jun; 47(6):1335-9. PubMed ID: 2769993
    [No Abstract]   [Full Text] [Related]  

  • 6. Bioavailability of elcatonin (ASU1,7-eel calcitonin) after intranasal administration to rats and dogs.
    Manzoni C; Monti C; Valente M
    Pharmacol Res; 1989; 21(1):105-6. PubMed ID: 2726652
    [No Abstract]   [Full Text] [Related]  

  • 7. Biological accessibility of calcitonin and osteocalcin marked 125J for rats.
    Ryszka F; Krupej J; Dolińska B; Gawronski M; Jeszka H; Ustjanycz E; Suszka-Switek A
    Boll Chim Farm; 1994 Nov; 133(10):659-61. PubMed ID: 7865197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. pH-sensitive microsphere delivery increases oral bioavailability of calcitonin.
    Lamprecht A; Yamamoto H; Takeuchi H; Kawashima Y
    J Control Release; 2004 Jul; 98(1):1-9. PubMed ID: 15245884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the biological activity of unmodified synthetic eel calcitonin rectal capsules. Comparison with intramuscular administration and placebo.
    Fiore CE; Fiorito S; Foti R; Motta M; Incognito C; Grasso G
    Int J Clin Pharmacol Res; 1992; 12(4):185-9. PubMed ID: 1338433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy: a randomized controlled trial.
    Bem R; Jirkovská A; Fejfarová V; Skibová J; Jude EB
    Diabetes Care; 2006 Jun; 29(6):1392-4. PubMed ID: 16732029
    [No Abstract]   [Full Text] [Related]  

  • 11. Randomized, double-blind, clinically controlled trial of intranasal calcitonin treatment in patients with hip fracture.
    Huusko TM; Karppi P; Kautiainen H; Suominen H; Avikainen V; Sulkava R
    Calcif Tissue Int; 2002 Dec; 71(6):478-84. PubMed ID: 12370798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [An intranasal method of administration of calcitrin to steroid-dependent patients with bronchial asthma].
    Chuchalin AG; Baranova IA; Berova MM
    Klin Med (Mosk); 1991 Sep; 69(9):24-6. PubMed ID: 1803141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical tolerance of calcitonin as a function of the mode of administration. Value of non-injectable forms].
    Eisinger J
    Rev Rhum Mal Osteoartic; 1987 Jan; 54(1):65-7. PubMed ID: 3563370
    [No Abstract]   [Full Text] [Related]  

  • 14. Intranasal calcitonin for prevention and treatment of osteoporosis.
    Christiansen C
    Ann Chir Gynaecol; 1988; 77(5-6):229-34. PubMed ID: 3076050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Data comparison of osteoporosis patients demonstrates nasal administration is not optimal].
    MMW Fortschr Med; 2004 Feb; 146(7):62. PubMed ID: 15347062
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
    Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C
    Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin.
    Välimäki MJ; Kinnunen K; Volin L; Tähtelä R; Löyttyniemi E; Laitinen K; Mäkelä P; Keto P; Ruutu T
    Bone Marrow Transplant; 1999 Feb; 23(4):355-61. PubMed ID: 10100579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (i.m.) or placebo injection in normal subjects.
    Reginster JY; Denis D; Albert A; Franchimont P
    Bone Miner; 1987 Apr; 2(2):133-40. PubMed ID: 3504725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [ICTP].
    Yamamoto I
    Nihon Rinsho; 1999 Sep; 57 Suppl():211-4. PubMed ID: 10543089
    [No Abstract]   [Full Text] [Related]  

  • 20. Alternative routes of peptide hormone administration.
    Pontiroli AE; Secchi A; Alberetto M
    Spec Top Endocrinol Metab; 1985; 7():77-99. PubMed ID: 3914099
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.